LLY

1,017.19

-2.72%↓

JNJ

244.07

+0.3%↑

ABBV

227.12

-2.44%↓

NVS

165.06

-0.79%↓

MRK

120.66

-0.62%↓

LLY

1,017.19

-2.72%↓

JNJ

244.07

+0.3%↑

ABBV

227.12

-2.44%↓

NVS

165.06

-0.79%↓

MRK

120.66

-0.62%↓

LLY

1,017.19

-2.72%↓

JNJ

244.07

+0.3%↑

ABBV

227.12

-2.44%↓

NVS

165.06

-0.79%↓

MRK

120.66

-0.62%↓

LLY

1,017.19

-2.72%↓

JNJ

244.07

+0.3%↑

ABBV

227.12

-2.44%↓

NVS

165.06

-0.79%↓

MRK

120.66

-0.62%↓

LLY

1,017.19

-2.72%↓

JNJ

244.07

+0.3%↑

ABBV

227.12

-2.44%↓

NVS

165.06

-0.79%↓

MRK

120.66

-0.62%↓

Kodu・Aktsiate loetelu・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Avatud

SektorTervishoid

42.73 3.24

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

41.39

Max

42.8

Põhinäitajad
By Trading Economics
Sissetulek	-6.2M -91M
Kasumimarginaal	-867.293
Töötajad	316
EBITDA	4M -90M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+32.59% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	26. veebr 2026

Turustatistika
By TradingEconomics
Turukapital	-25M 3.2B
Eelmine avamishind	39.49
Eelmine sulgemishind	42.73

Uudiste sentiment

By Acuity

50%

165 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

34.81 / 38.24 Toetus ja vastupanu

Xenon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

17. veebr 2026, 23:44 UTC

Kuumad aktsiad

Stocks to Watch: La-Z-Boy, Palo Alto Networks, Caesars

17. veebr 2026, 23:20 UTC

Tulu

Palo Alto Networks Lifts FY26 Revenue Outlook as 2Q Profit Jumps -- Update

17. veebr 2026, 22:57 UTC

Tulu

Santos Fiscal Year Net Profit Falls 33%, Nears Start of Alaska Project

17. veebr 2026, 21:59 UTC

Tulu

Palo Alto Networks Lifts FY26 Revenue Outlook as 2Q Profit Jumps

17. veebr 2026, 23:54 UTC

Market Talk

Nikkei May Rise as Fears About AI Disruption Ease -- Market Talk

17. veebr 2026, 23:54 UTC

Market Talk

Global Equities Roundup: Market Talk

17. veebr 2026, 23:54 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. veebr 2026, 23:45 UTC

Market Talk

Suncorp's Outperformance of IAG Could Be Hard to Sustain -- Market Talk

17. veebr 2026, 23:19 UTC

Tulu

Palo Alto's Guidance Overshadows Strong Earnings. Its Stock Is Down. -- Barrons.com

17. veebr 2026, 23:15 UTC

Tulu

Palo Alto's Guidance Overshadows Strong Earnings. Its Stock Is Down. -- Barrons.com

17. veebr 2026, 22:58 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Netflix Would Operate Warner's Studios, HBO Largely the Same -- Market Talk

17. veebr 2026, 22:58 UTC

Omandamised, ülevõtmised, äriostud

BlueScope Steel: Board Committed to Optimizing Value For Shareholders

17. veebr 2026, 22:57 UTC

Omandamised, ülevõtmised, äriostud

BlueScope Steel to Consider Revised SGH, Steel Dynamics Takeover Bid

17. veebr 2026, 22:50 UTC

Omandamised, ülevõtmised, äriostud

Agnico-Eagle Mines Acquired 662,780 Common Shrs of Maple Gold Mines at C$2.45 Per Common Shr >AEM.T

17. veebr 2026, 22:44 UTC

Tulu

Palo Alto Reports Strong Earnings. Its Stock Is Down. -- Barrons.com

17. veebr 2026, 22:42 UTC

Tulu

Santos FY Net Profit Falls 33%, Nears Start of Alaska Project

17. veebr 2026, 22:36 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Netflix Sarandos: Paramount Causing Confusion Around Warner Deal -- Market Talk

17. veebr 2026, 22:36 UTC

Tulu

Santos Final Dividend 10.3 U.S. Cents/Security

17. veebr 2026, 22:36 UTC

Tulu

Santos FY Underlying Profit US$898 Million, Down 25%

17. veebr 2026, 22:35 UTC

Tulu

Santos FY Revenue US$4.94 Billion, Down 8%

17. veebr 2026, 22:35 UTC

Tulu

Correct: Santos FY Net Profit US$818 Million, Down 33%

17. veebr 2026, 22:35 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Buys New York Times Stock; Sells Apple, Bank of America, Amazon In 4Q -- Barrons.com

17. veebr 2026, 22:34 UTC

Tulu

Santos FY Net Profit US$818 Billion, Down 33%

17. veebr 2026, 22:02 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Pares Stakes in Apple and BofA, Adds New York Times Position -- Update

17. veebr 2026, 21:50 UTC

Omandamised, ülevõtmised, äriostud

Steel Dynamics: SGH Would Buy BlueScope, On-sell North American Operations to SDI, As Earlier Proposed

17. veebr 2026, 21:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

17. veebr 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17. veebr 2026, 21:49 UTC

Omandamised, ülevõtmised, äriostud

Steel Dynamics Says Revised Proposal Continues to Present Highly Strategic Opportunity For SDI Shareholders

17. veebr 2026, 21:48 UTC

Omandamised, ülevõtmised, äriostud

Steel Dynamics: BlueScope Offer a 56% Premium to 52-Week Volume Weighted Average Price

17. veebr 2026, 21:48 UTC

Omandamised, ülevõtmised, äriostud

Steel Dynamics: Consideration To Be Comprised Entirely of Cash

Võrdlus sarnastega

Hinnamuutus

Xenon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

32.59% tõus

12 kuu keskmine prognoos

Keskmine 55 USD 32.59%

Kõrge 66 USD

Madal 44 USD

Põhineb 10 Wall Streeti analüütiku instrumendi Xenon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

10 ratings

Osta

Hoia

Müü

Põhineb 10 analüütiku instrumendi Xenon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

34.81 / 38.24Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

165 / 351 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.